Daniel J Lightwood
Overview
Explore the profile of Daniel J Lightwood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Starkie D, Arber C, Baker T, Lightwood D, Wray S
MAbs
. 2024 Dec;
16(1):2436102.
PMID: 39665388
Microtubule-associated protein tau is inextricably linked to a group of clinically diverse neurodegenerative diseases termed tauopathies. The ratio balance of the major tau splicing isoform groups (3 R- and 4 ...
2.
Donnellan F, Rayaprolu V, Rijal P, ODowd V, Parvate A, Callaway H, et al.
bioRxiv
. 2024 Jul;
PMID: 38979279
Ebolavirus disease (EVD) is caused by multiple species of . Monoclonal antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic approved for treatment of EVD caused...
3.
Agrafiotis A, Neumeier D, Hong K, Chowdhury T, Ehling R, Kuhn R, et al.
iScience
. 2023 Feb;
26(3):106055.
PMID: 36852274
Although new genomics-based pipelines have potential to augment antibody discovery, these methods remain in their infancy due to an incomplete understanding of the selection process that governs B cell clonal...
4.
Neumeier D, Yermanos A, Agrafiotis A, Csepregi L, Chowdhury T, Ehling R, et al.
Proc Natl Acad Sci U S A
. 2022 Apr;
119(18):e2113766119.
PMID: 35486691
The capacity of humoral B cell-mediated immunity to effectively respond to and protect against pathogenic infections is largely driven by the presence of a diverse repertoire of polyclonal antibodies in...
5.
Lightwood D, Munro R, Porter J, McMillan D, Carrington B, Turner A, et al.
Nat Commun
. 2021 Jan;
12(1):583.
PMID: 33495445
We have recently described the development of a series of small-molecule inhibitors of human tumour necrosis factor (TNF) that stabilise an open, asymmetric, signalling-deficient form of the soluble TNF trimer....
6.
Josephides D, Davoli S, Whitley W, Ruis R, Salter R, Gokkaya S, et al.
SLAS Technol
. 2020 Jan;
25(2):177-189.
PMID: 31941402
The primary goal of bioprocess cell line development is to obtain high product yields from robustly growing and well-defined clonal cell lines in timelines measured in weeks rather than months....
7.
Rijal P, Elias S, Rosendo Machado S, Xiao J, Schimanski L, ODowd V, et al.
Cell Rep
. 2019 Apr;
27(1):172-186.e7.
PMID: 30943399
We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP) and boosted with modified vaccinia virus Ankara. Among 82 antibodies isolated...
8.
Starkie D, Compson J, Rapecki S, Lightwood D
PLoS One
. 2016 Mar;
11(3):e0152282.
PMID: 27022949
Single B cell screening strategies, which avoid both hybridoma fusion and combinatorial display, have emerged as important technologies for efficiently sampling the natural antibody repertoire of immunized animals and humans....
9.
Clargo A, Hudson A, Ndlovu W, Wootton R, Cremin L, ODowd V, et al.
MAbs
. 2014 Jan;
6(1):143-59.
PMID: 24423622
Single B cell technologies, which avoid traditional hybridoma fusion and combinatorial display, provide a means to interrogate the naturally-selected antibody repertoire of immunized animals. Many methods enable the sampling of...
10.
Davies N, Compson J, MacKenzie B, ODowd V, Oxbrow A, Heads J, et al.
Clin Vaccine Immunol
. 2013 Jan;
20(3):377-90.
PMID: 23324518
Clostridium difficile infections are a major cause of antibiotic-associated diarrhea in hospital and care facility patients. In spite of the availability of effective antibiotic treatments, C. difficile infection (CDI) is...